Citations

Clear

3942 citation(s) found for "To, Van".

Three‐Year Outcomes With a Supra‐Annular, Self‐Expanding Bioprosthesis and a Pericardial Wrap—The FORWARD PRO Study
Mieghem, Nicolas M. Van , Manoharan, Ganesh, Lancellotti, Patrizio , Danenberg, Haim , Scholtz, Werner , Brecker, Stephen , Ruge, Hendrik, Opdahl, Anders , Amoroso, Giovanni , Petronio, Anna Sonia , Nickenig, Georg, Harnath, Axel, Oh, Jae K. , Eisenberg, Ruth , Grube, Eberhard, Ruge, Hendrik , Van Mieghem, Nicolas M , Kornowski, Ran , Bedogni, Francesco , Windecker, Stephan , Tamburino, Corrado , Thiele, Hölger , Fiorina, Claudia , Kempfert, Jörg

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 17, 2024 | Volume: 105 | Issue: 3 | Pages: 577-587

10.1002/ccd.31335 | PMID 39686582 Get It

ABSTRACTBackgroundThe self‐expanding, supra‐annular Evolut valve is an established platform for Transcatheter Aortic Valve Implantation (TAVI). Evolut PRO introduced an outer sealing wrap to mitigate paravalvular leakage. We evaluated the 3‐year clinical outcomes and valve performance of the Evolut PRO in standard clinical practice for severe aortic stenosis (AS) patients at intermediate or higher risk for surgery.MethodsThe FORWARD PRO prospective, single‐arm, multicentre, post‐market clinical study enrolled 638 patients with native aortic valve stenosis or failed surgical bioprosthetic aortic valve undergoing TAVI, at intermediate or high risk, with the Evolut PRO valve. Clinical and serial echocardiographic outcomes were followed‐up for 3 years.ResultsTAVI using Evolut PRO was attempted in 629 AS patients (implanted in 97%) (mean age 81.7 years; STS PROM score, 4.7%). At 3 years all‐cause mortality was 25.0%, disabling stroke 6.5% (all‐cause mortality or disabling stroke, 28.5%) and rate of new permanent pacemaker implantation 24.7%. Excellent valve haemodynamics were maintained (mean gradient 8.8 ± 4.7 mm Hg; mean effective orifice area 2.0 ± 0.5 cm2) at 3 years. In a paired analysis of patients with ≥ mild paravalvular leakage (PVL) at discharge, more than two‐thirds demonstrated improved PVL at 3 years. Patients with ≥ mild PVL at discharge had higher median total calcium volume than those with no/trace PVL (p < 0.001).ConclusionsIn clinical practice TAVI with the Evolut PRO valve is associated with favorable clinical outcomes and excellent haemodynamic performance out to 3 years. The observation of improvements in PVL over time warrants further research.
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
Morris, Van K. , Kennedy, Erin B. , Amin, Manik , Aranha, Olivia , Benson, Al B. , Dorth, Jennifer A. , Horowitz, David P. , Kennecke, Hagen F. , Kim, Stéfano , Kreppel, Lillian, Rajdev, Lakshmi , Mettu, Niharika B , Riechelmann, Rachel , Sio, Terence T , Eng, Cathy , Riechelmann, Rachel P. , Sio, Terence T. , Eng, Cathy

Mayo Clinic

Journal of Clinical Oncology | December 16, 2024 | Volume: 43 | Issue: 5 | Pages: 605-615

10.1200/jco-24-02120 | PMID 39680825 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgement. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard-of-care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only). PURPOSE To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer. METHODS A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations. RESULTS The systematic review contained three randomized controlled trials and three nonrandomized studies of interventions that were relevant to the guideline topic and informed the recommendations. RECOMMENDATIONS Mitomycin-C (MMC) with a fluoropyrimidine (fluorouracil [FU] or capecitabine) is recommended as the radiosensitizing component of chemoradiation (CRT) for anal cancer; the Expert Panel recognizes that capecitabine is often used as an orally administered alternative to FU and is currently being used in ongoing clinical trials. Cisplatin with FU is an additional chemotherapy combination that may be recommended as radiosensitizing chemotherapy. Because of the myelosuppression associated with MMC, the preferable regimen for patients with immunosuppression is cisplatin and FU. Cisplatin is not recommended for patients with renal dysfunction, significant neuropathy, or hearing loss, and there is no evidence to recommend substituting carboplatin for cisplatin. Dose and schedule options for recommended chemotherapy agents are included within the full text of the guideline. Routine induction chemotherapy before CRT and additional chemotherapy after CRT are not recommended for patients with localized anal cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
National Trends and Benchmarks for Operative Time and Hospital Length of Stay in Parotidectomies
Calcano, Gabriela A. , Rourk, Katelyn S. , Glasgow, Amy E. , Henson, Jeanne, Tasche, Kendall K. , Abel, Kathryn M. Van , Moore, Eric J. , Glasgow, Amy, Henson, Jammie, Yin, Linda X , Van Abel, Kathryn M , Habermann, Elizabeth B. , Henson, Jammie, Price, Daniel L. , Yin, Linda X.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 15, 2024 | Volume: 172 | Issue: 3 | Pages: 913-921

10.1002/ohn.1084 | PMID 39675031 Get It

AbstractObjectiveThe extent of parotidectomy for benign tumors has de‐escalated in the United States. We aim to define modern benchmarks for operative time and hospital length of stay (LOS) in parotidectomy and identify risk factors that may prolong these benchmarks.Study DesignThis is a retrospective cross‐sectional study of all adults who underwent parotidectomy for a primary parotid neoplasm between January 2011 and December 2021 using the American College of Surgeons National Surgical Quality Improvement Program database.MethodsThe extent of parotidectomy was defined using Current Procedural Terminology codes. Prolonged operative time and LOS were defined as above the 75th percentile (longer than 194 minutes and more than 1 day, respectively). Multivariable logistic regression was used to identify patient and surgical risk factors that predict prolonged operative time or LOS.ResultsBenign parotidectomies are mostly performed as outpatient procedures in the United States (average LOS <1 day). Prolonged operative time was independently associated with malignant tumors versus benign tumors (adjusted odds ratio [aOR]: 2.7, 95% confidence interval [CI]: 2.4‐3.0), total parotidectomy with facial nerve sacrifice versus lesser extent of parotidectomy (aOR: 2.3, 95% CI: 1.7‐3.0), and simultaneous reconstructive procedures versus none (P < .001 for all). These features were similarly independently associated with prolonged LOS (P < .001 for all). Complication rates were universally low.ConclusionThe majority of superficial parotidectomies in this country are performed as outpatient procedures requiring <3 hours of operative time, with low complication rates. Malignant tumors, greater extent of parotidectomy, and simultaneous procedures were independently associated with prolonged operative time and LOS. These national benchmarks can inform operating room and hospital bed resource assignments.
Artificial intelligence powers regenerative medicine into predictive realm
Garmany, Armin , Terzic, André , Terzic, Andre

Mayo Clinic

Regenerative Medicine | December 11, 2024 | Volume: 19 | Issue: 12 | Pages: 611-616

10.1080/17460751.2024.2437281 | PMID 39660914 Get It

(230) EXPLORING HOW BMI SHAPES THE SUCCESS OF INFLATABLE PENILE PROSTHESIS SURGERY: MULTI-CENTER STUDY INSIGHTS
Hammad, Muhammed , Gross, MS, Andrianne, Robert, Burnett, AL, Gross, Kelli, Hatzichristodoulou, G, Lentz, A, Modgil, Vaibhav , Perito, P, Hotaling, JM, Park, SH, Pearce, Ian , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez-Sarmiento, A, Renterghem, Katrien Van, Warner, J, Ziegelmann, Matthew , Hsieh, TC, Karthikeyan, Hridhay, Simhan, J, Yafi, FA, collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW, Hammad, Muhammed A M , Miller, John D. , Chawareb, Elia Abou , Amini, Erfan , Hatzichristodoulou, Georgios , Osmonov, D, Perito, P, Suarez‐Sarmiento, Alfredo, Azad, Babak Kazemzadeh , Jenkins, Lawrence C. , Jones, James M. , Simhan, Jay , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW

Mayo Clinic

The Journal of Sexual Medicine | December 11, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.224 Get It

Abstract Introduction Obesity, defined as an elevated Body Mass Index (BMI) &gt;30, is a prevalent public health concern with far-reaching implications for various medical procedures and outcomes. In the context of inflatable penile prosthesis placement (IPP), where patient well-being and surgical success are of paramount importance, the impact of obesity on postoperative and intraoperative complications warrants thorough investigation. Objective We aimed to investigate the impact of BMI on both postoperative and intraoperative complications in an international, multi-institutional cohort of patients who underwent IPP placement. Methods We performed a retrospective chart review of 4,398 cases. These cases were divided into two distinct groups based on BMI: less than 30 (n = 2,260) and greater than or equal to 30 (n = 2,138). The study assessed various surgical factors as well as complications, including overall complications, corporal scarring, incontinence, intraoperative complications, proximal perforation, distal perforation, proximal crossover, distal crossover, and urethral injury. Results Our analysis revealed that there were no statistically significant differences in intraoperative or postoperative complications between the two BMI categories. Notably, proximal corporal measurement was significantly higher for &gt;30 BMI group with 1858 (86.9%) compared to 1919 (84.9%) for &lt;30 BMI group, (p = &lt; 0.001). The incidence rates for overall complications (30.2% vs. 28.7%; p = 0.164), corporal scarring (18.2% vs. 16.7%; p = 0.36), incontinence (3.53% vs. 3.13%; p = 0.076), intraoperative complications (1.94% vs. 1.68%; p = 0.253), and specific complications all exhibited no significant differences. Similarly, post-operative complications, including both non-infectious (6.99% vs. 6.22%; p = 0.215) and infectious (2.61% vs. 1.87%; p = 0.165) complications, did not significantly vary between BMI categories. Conclusions Our findings indicate that BMI does not exert a statistically significant influence on postoperative and intraoperative complications in the context of high-volume prosthetic urology. In the absence of any other differences between patients of differing BMIs, the IPP industry may need to consider device specific alterations with pump tubing length in obese patients. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast, Clarus Therapeutics, Antares Pharma, Acerus.
(165) NOVEL INSIGHTS ON PERIOPERATIVE ANTIMICROBIAL PROPHYLAXIS PATTERNS FOR INFLATABLE PENILE PROSTHESIS: FINDINGS FROM A LARGE MULTINATIONAL COLLABORATIVE
Hammad, MAM, Gross, MS, Swerdloff, Daniel , Miller, Justin , Andrianne, Robert, Burnett, AL, Gross, Kelli, Hatzichristodoulou, G, Lentz, A, Osmonov, Daniar , Jones, Adam , Modgil, Vaibhav , Perito, P, Hotaling, JM, Pearce, Ian , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez-Sarmiento, A, Warner, J, Ziegelmann, Matthew , Hsieh, TC, Simhan, Jay , Yafi, FA, collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW, Hammad, Muhammed , Hammad, Muhammed A M , Azad, Babak Kazemzadeh , Chawareb, Elia Abou , Hatzichristodoulou, Georgios , Park, SH, Suarez‐Sarmiento, Alfredo, Renterghem, Koenraad van , Jenkins, Lawrence C. , Jones, James M. , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW

Mayo Clinic

The Journal of Sexual Medicine | December 11, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.162 Get It

Abstract Introduction Inflatable penile prosthesis (IPP) surgery is a well-established treatment for erectile dysfunction (ED). There is little information in the literature regarding the utilization of perioperative antimicrobial prophylaxis in primary and revision IPP surgeries. Objective We investigated the patterns of perioperative antimicrobial prophylaxis among a large multinational cohort of primary and revision IPP surgeries. Methods We conducted a retrospective analysis of 5,400 patients (4,187 primary IPP patients and 849 revision IPP patients) from our Prosthetic Urology Multi-Institutional Partnership (PUMP) institutions. Usage data for intravenous (IV), preoperative oral, and postoperative oral antimicrobials were analyzed. We specifically assessed patient profiles, antimicrobial selection, and antimicrobial duration. Multivariate statistical analyses were conducted to identify significant variations between primary and revision surgeries. Results For patients undergoing primary IPP placement, 81.9% received IV antibiotics for &lt;24 hours whereas 18.1% received IV antibiotics for &gt;24 hours. Preoperative oral antimicrobials were used in 59.4% of patients and 99.4% received postoperative oral antimicrobials. The overall infection rate for primary implants was 2%. Notably, quinolone administration shows a higher postoperative infection rate (11.4%) compared to gentamicin (1.9%), cephalosporin (0%), and vancomycin (1.0%). Multivariable regression analysis identifies factors such as a history of infection, diabetes, and priapism as predictors for postoperative infections. Furthermore, the study finds that perioperative antifungal use is associated with a decreased risk of infection. Conclusions This study provides valuable insights into the patterns of perioperative antimicrobial prophylaxis. Duration, type, and route of antibiotics given preoperatively or postoperatively do not affect postoperative infection rates among high volume prosthetic urologists. Giving IV antibiotics for more than 24 hours does not affect postoperative infection. Perioperative antifungals are a protective factor. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast, Clarus Therapeutics, Antares Pharma, Acerus.
(012) USE OF REAR TIP EXTENDERS IS ASSOCIATED WITH INCREASED RISK OF POST-OPERATIVE COMPLICATIONS AND PENILE PROSTHESIS REVISION IN PATIENTS UNDERGOING PRIMARY INFLATABLE PENILE PROSTHESIS PLACEMENT: RESULTS FROM A LARGE MULTI-INSTITUTIONAL COLLABORATIVE
Dalimov, Zafardjan , Ivan, SJ, Barham, David , Sadeghi‐Nejad, Hossein , Modgi, V, Andrianne, Robert, Sempels, Maxime, Hsieh, Tung‐Chin , Hatzichristodoulou, Georgios , Osmonov, Daniar , Lentz, A, Perito, Paul , Hotaling, James M. , Park, SH, Ziegelmann, Matthew , Pearce, Ian , Gross, MS, Yafi, FA, Simhan, J, Hammad, Muhammed , Hammad, Muhammed A M , Ivan, SJ, Hammad, M, Lentz, A, Renterghem, Koenraad van , Simhan, Jay

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.010 Get It

Abstract Introduction The utilization of rear tip extenders (RTE) is often imperative during Inflatable Penile Prosthesis (IPP) placement. The impact of RTE on perioperative morbidity of IPP surgery is underexplored. Objective In this study, we assess intraoperative and postoperative outcomes among patients undergoing primary IPP implantation with or without RTE. Methods We performed a multicenter, retrospective analysis of men undergoing primary IPP placement between July 2016 and July 2021. A total of 4308 patients were identified, of which 2963 had no RTE and 1345 had RTE. After 1:1 propensity score matching for all confounding variables, 840 patients without RTE were compared to patients with RTE for intraoperative and postoperative outcomes. Chi-square and Mann–Whitney tests were used for statistical analysis for categorial and continuous variables respectively. For multivariable analysis, we used a forward stepwise model and included significant variables found on preoperative characteristics of patients. Kaplan–Meier time to event analysis were compared with Mantel-Cox log-rank test. Results Patients with RTE use had more postoperative complications (9.6% vs 5.2%, p &lt; 0.001). More specifically, RTE patients had more episodes of postoperative hematoma and bleeding (2.0% vs 0.7%, p = 0.033), device malfunction (2.7% vs 1.8%, p = 0.006), and glans-related complications (0.8% vs 0, p = 0.015). On multivariable analysis, use of RTE (OR 1.58, 95% CI 1.07-2.34, p = 0.021), AMS 700 series device (OR 1.93, 95% CI 1.27-2.94, p = 0.002), penoscrotal approach (OR 2.60, 95% CI 1.61-4.18, p &lt; 0.001), and older age (OR 1.02, 95% CI 1.00-1.04, p = 0.035) were associated with increased risk of postoperative complications. Patients with RTE use had increased rate of postoperative IPP revision (5.0% vs 2.1%, p = 0.002). The use of RTE (OR 1.71, 95% CI 1.00-2.90, p = 0.046), AMS 700 series device (OR 1.73, 95% CI 1.01-2.97, p = 0.048), penoscrotal approach (OR 3.16, 95% CI 1.63-6.17, p &lt; 0.001), and history of Peyronie’s disease (OR 2.24, 95% CI 1.31-3.82, p = 0.003) were associated with increased risk of postoperative IPP revision or explantation. On Kaplan–Meier analysis, use of RTE was associated with increased risk of postoperative complications and IPP revision or explantation within 48 months (log rank p = 0.001 and p = 0.002 respectively). Conclusions In this large multi-institutional cohort, patients with RTE experienced more hematoma, device malfunctioning, and glans related post operative complications. The use of RTE is an independent predictor of post-operative complications and IPP revision or explanation. Disclosure No.
New findings regarding predictors of Poor Corporal Integrity in Penile Implant Recipients: A Multicenter International Invesigation
Chang, Chrystal , Barham, David W. , Dalimov, Zafardjan , Swerdloff, Daniel , Sadeghi‐Nejad, Hossein , Andrianne, Robert, Sempels, Maxime, Hsieh, Tung‐Chin , Hatzichristodoulou, Georgios , Hammad, Muhammed , Lentz, Aaron , Perito, Paul , Suarez‐Sarmiento, Alfredo, Hotaling, James M. , Gross, Kelli, Park, Sung Hun, Warner, Jonathan N. , Ziegelmann, Matthew , Modgil, Vaibhav , Jones, Adam , Pearce, Ian , Gross, Martin , Yafi, Faysal A. , Simhan, Jay , Miller, Jake , Jones, James M , Ziegelmann, Matthew , Yafi, Faysal A , Hammad, Muhammed A M , Osmonov, Daniar , Jones, James M. , Renterghem, Koenraad van , Burnett, Arthur L. “Bud”

Mayo Clinic

BJU International | December 10, 2024 | Volume: 135 | Issue: 3 | Pages: 528-534

10.1111/bju.16607 | PMID 39658322 Get It

Objectives To evaluate the pre‐ and intraoperative variables that impact the integrity of the corporal bodies over time after inflatable penile prosthesis (IPP) placement, as predictors of intraoperative corporal perforation and delayed cylinder complications have not been well characterized. Patients and Methods We retrospectively reviewed a 16‐centre multi‐institutional database of IPP surgeries performed by experienced implanters from 2016 to 2021. Poor corporal integrity (PCI) was defined as intraoperative (iPCI) corporal complications or postoperative (pPCI) corporal complications. Multivariable analysis was performed to identify independent predictors of PCI, iPCI, and pPCI. Primary outcomes included intra‐ and postoperative corporal complications. Results We identified 5153 patients for analysis from 5406 IPP cases, finding 152 (2.95%) cases of PCI. On multivariable analysis, predictors of PCI included revision IPP surgery (odds ratio [OR] 8.16, 95% confidence interval [CI] 5.15–12.92; P < 0.001), sequential dilatation (OR 2.12, 95% CI 1.32–3.39; P = 0.002), coronary artery disease (CAD)/peripheral vascular disease (PVD) (OR 1.81, 95% CI 1.18–2.77; P = 0.006), older age (OR 1.02, 95% CI 1.01–1.04; P = 0.013), and corporal scarring (OR 1.58, 95% CI 1.0–2.5; P = 0.049). Predictors of iPCI included revision IPP surgery (OR 7.34, 95% CI 4.18–12.88; P < 0.001), corporal scarring (OR 2.77, 95% CI 1.64–4.69; P < 0.001), radiation therapy (OR 2.25, 95% CI 1.0–5.04; P = 0.049), and older age (OR 1.03, 95% CI 1.0–1.05; P = 0.025). Revision IPP surgery (OR 7.92, 95% CI 3.69–17.01; P < 0.001), sequential dilatation (OR 3.4, 95% CI 1.61–7.19; P = 0.001), CAD/PVD (OR 2.98, 95% CI 1.56–5.72; P = 0.001), and history of priapism (OR 3.59, 95% CI 1.08–11.99; P = 0.038) were predictive of pPCI. Conclusion Coronary artery disease/PVD, being of older age, having corporal scarring, undergoing IPP revision surgery and sequential dilatation were predictive risk factors for complications associated with PCI. Identifying patients who are at risk of having PCI may improve patient‐specific counselling, consideration of referral to more experienced implanters, and surgical planning to potentially promote longer‐term device viability.
(149) NEW FINDINGS REGARDING PERIOPERATIVE INFLATABLE PENILE PROSTHESIS ANTIMICROBIAL PROPHYLAXIS PATTERNS FROM A LARGE MULTINATIONAL COLLABORATION
Hammad, MAM, Gross, MS, Swerdloff, Daniel , Miller, Justin , Alkhayal, A, Alrabeeah, K, Andrianne, Robert, Burnett, AL, Gross, Kelli, Hatzichristodoulou, G, Lentz, A, Osmonov, Daniar , Jones, Adam , Modgil, Vaibhav , Perito, P, Hotaling, JM, Pearce, Ian , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez-Sarmiento, A, Warner, J, Ziegelmann, Matthew , Hsieh, TC, Simhan, Jay , Yafi, FA, collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW, Hammad, Muhammed , Azad, Babak Kazemzadeh , Chawareb, Elia Abou , Hatzichristodoulou, Georgios , Park, SH, Suarez‐Sarmiento, Alfredo, Renterghem, Koenraad van , Jenkins, Lawrence C. , Jones, James M. , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_6 | Pages: No page available

10.1093/jsxmed/qdae161.121 Get It

Abstract Introduction Inflatable penile prosthesis (IPP) surgery is a well-established treatment for erectile dysfunction (ED). There is little information in the literature regarding the utilization of perioperative antimicrobial prophylaxis in primary and revision IPP surgeries. Objective We investigated the patterns of perioperative antimicrobial prophylaxis among a large multinational cohort of primary and revision IPP surgeries. Methods We conducted a retrospective analysis of 5400 patients (4187 primary IPP patients and 849 revision IPP patients) from our Prosthetic Urology Multi-Institutional Partnership (PUMP) institutions. Usage data for intravenous (IV), preoperative oral, and postoperative oral antimicrobials were analyzed. We specifically assessed patient profiles, antimicrobial selection, and antimicrobial duration. Multivariate statistical analyses were conducted to identify significant variations between primary and revision surgeries. Results For patients undergoing primary IPP placement, 81.9% received IV antibiotics for &lt;24 hours whereas 18.1% received IV antibiotics for &gt;24 hours. Preoperative oral antimicrobials were used in 59.4% of patients and 99.4% received postoperative oral antimicrobials. The overall infection rate for primary implants was 2%. Notably, quinolone administration shows a higher postoperative infection rate (11.4%) compared to gentamicin (1.9%), cephalosporin (0%), and vancomycin (1.0%). Multivariable regression analysis identifies factors such as a history of infection, diabetes, and priapism as predictors for postoperative infections. Furthermore, the study finds that perioperative antifungal use is associated with a decreased risk of infection. Conclusions This study provides valuable insights into the patterns of perioperative antimicrobial prophylaxis. Duration, type, and route of antibiotics given preoperatively or postoperatively do not affect postoperative infection rates among high volume prosthetic urologists. Giving IV antibiotics for more than 24 hours does not affect postoperative infection. Perioperative antifungals are a protective factor. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast, Clarus Therapeutics, Antares Pharma, Acerus.
The Fate of the Frozen Bone Flap: Quantitative and Volumetric Assessment Following Cranioplasty Using the Autologous Bone Flap
Cherukuri, Sai , Zheng, Eugene E. , Pazelli, Alexandre Meira, Sears, Victoria A. , Gibreel, Waleed , Cherukuri, Sai K, Van Gompel, Jamie, Meira Pazelli, Alexandre, Gibreel, Waleed , Gompel, Jamie J. Van , Vierkant, Robert A. , Mardini, Samir , Morris, Jonathan M.

Mayo Clinic

Journal of Craniofacial Surgery | December 10, 2024 | Volume: 36 | Issue: 2 | Pages: 508-512

10.1097/scs.0000000000010960 | PMID 39656195 Get It

Objective: The pattern, rate, and natural history of bone flap resorption following cranioplasty with frozen, autologous bone flap has not been fully defined. The authors sought to quantify the progression and natural history of bone flap resorption. Methods: Patients who had craniectomy and delayed cranioplasty with stored, frozen bone flap between 2012 and 2022 were included in this study. Results: Ninety patients (63% male) were included, with a median age of 44.8 years (range: 4.2–84.4 y) at the time of autologous bone flap cranioplasty. Delayed, autologous cranioplasty occurred at a median time of 29.5 days (range: 2 d–10 y) from the index craniectomy. The median follow-up was 16.6 months (range: 3.4–85.4 mo). Radiographically quantifiable bone flap resorption occurred in 50 patients (56%). During the follow-up, the average percentage volume loss was 17%, with a nonlinear pattern of resorption. Following delayed, autologous cranioplasty, 11 patients had clinically significant bone flap resorption requiring secondary alloplastic cranioplasty at a median time of 13.8 months (range: 5.9–57.2 mo), with a mean percentage volume loss of 61%. Younger age was a risk factor for bone flap resorption (P < 0.05), whereas active smoking, presence of comorbidities, and number of days of bone flap storage were not risk factors for bone flap resorption. Penalized B-spline regression analysis showed that bone flap resorption followed a nonlinear pattern. Conclusion: Radiographically quantifiable bone flap resorption occurred in about 56% of patients following delayed autologous cranioplasty. Resorption followed a non-linear pattern. Young age is a risk factor for bone flap resorption.